X
FDA rejects Amgen/UCB osteoporosis drug
https://pharmaphorum.com/news/fda-rejects-amgenucb-osteoporisis-drug/
UCB
Safety restrictions spell the end for Servier osteoporosis drug
Sales of Protelos hit by safety restrictions.
Amgen/UCB’s osteoporosis drug hit by cardio risk
Competitor to Amgen’s Epogen also moves closer to market
Pfizer’s fast-tracked leukaemia candidate could rival CAR-Ts
Antibody-drug conjugate with FDA gets six-month review.
Amgen/UCB reveal new osteoporosis drug data
But romosozumab missed secondary endpoint of non-vertebral fractures
Merck & Co. drops osteoporosis drug
Move boosts Amgen and UCB, which are developing a rival.
UCB: growing sales and growing bones
The specialist pharma company is set to expand into osteoporosis through its partnership with Amgen